OncoMatch/Clinical Trials/NCT06001086
A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
Is NCT06001086 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Disitamb Vedotin ,pyrotinib for breast cancer.
Treatment: Disitamb Vedotin ,pyrotinib — Evaluate the efficacy and safety of Disitamb Vedotin combined with pyrotinib in HER2 positive early breast cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) HER2 positive (evaluated as HER2 positive in local laboratories according to ASCOCAP guidelines)
evaluated as HER2 positive in local laboratories according to ASCOCAP guidelines
Allowed: ESR1 HR positive
tumors are either HR positive or HR negative (ER and PgR negative)
Allowed: PR (PGR) HR positive
tumors are either HR positive or HR negative (ER and PgR negative)
Allowed: ESR1 HR negative (ER negative)
tumors are either HR positive or HR negative (ER and PgR negative)
Allowed: PR (PGR) HR negative (PgR negative)
tumors are either HR positive or HR negative (ER and PgR negative)
Disease stage
Required: Stage II, III, IIIC (AJCC 8th edition)
Excluded: Stage IV
Clinical staging at visit (based on breast X-ray or breast MRI evaluation): Stage II-IIIC determined by the AJCC staging system, 8th edition. Stage IV breast cancer according to AJCC staging system version 8 [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: prior invasive breast cancer
Previous history of invasive breast cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify